5
|
Bertlich M, Stihl C, Lüsebrink E, Hellmuth JC, Scherer C, Freytag S, Spiegel JL, Stoycheva I, Canis M, Weiss BG, Ihler F, Haubner F. The course of subjective and objective chemosensory dysfunction in hospitalized patients with COVID-19: a 6-month follow-up. Eur Arch Otorhinolaryngol 2021; 278:4855-4861. [PMID: 33837835 PMCID: PMC8035606 DOI: 10.1007/s00405-021-06796-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Accepted: 03/31/2021] [Indexed: 01/06/2023]
Abstract
Purpose It has been established that the infection with SARS-CoV-2 may cause an impairment of chemosensory function. However, there is little data on the long-term effects of SARS-CoV-2 infection on chemosensory function.
Methods Twenty three SARS-CoV-2-positive patients diagnosed in spring 2020 with subjective hyposmia (out of 57 positive patients, 40.3%) were compared to SARS-CoV-2-positive patients without hyposmia (n = 19) and SARS-CoV-2-negative patients (n = 14). Chemosensory function was assessed by the Brief Smell Identification Test (BSIT), Taste Strips (TS), Visual Analogue Scales (VAS), and the SNOT-22. The initial cohort with hyposmia were also examined at 8 weeks and 6 months after initial examination. Results There were no differences between the SARS-CoV-2-positive cohort without hyposmia and negative controls in terms of BSIT (8.5 ± 2.6 vs. 10.2 ± 1.8), TS (3.4 ± 0.6 vs. 3.9 ± 0.3) or VAS (2.1 ± 1.3 vs. 1.1 ± 0.5); yet the SNOT-22 was significantly elevated (27.7 ± 11.2 vs. 16.4 ± 10.8). The SARS-CoV-2-positive group with hyposmia performed significantly poorer in BSIT (4.0 ± 1.7 vs. 8.5 ± 2.6/10.2 ± 1.8), TS (2.6 ± 1.3 vs. 3.4 ± 0.6/3.9 ± 0.3), and VAS (7.9 ± 2.2 vs. 2.1 ± 1.3/1.1 ± 0.5) compared to both control groups. At week 8 and month 6 control, six and five patients, respectively, still suffered from subjectively and objectively impaired chemosensory function. The other patients had recovered in both respects. Conclusion SARS-CoV-2 patients with subjectively impaired chemosensory function regularly perform poorly in objective measurements. About 70% of patients suffering from olfactory dysfunction in SARS-CoV-2 quickly recover—the rest still suffers from considerable impairment 6 months after infection.
Collapse
Affiliation(s)
- Mattis Bertlich
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Clemens Stihl
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Enzo Lüsebrink
- Medizinische Klinik und Poliklinik I, University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Johannes C Hellmuth
- Medizinische Klinik und Poliklinik III University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Clemens Scherer
- Medizinische Klinik und Poliklinik I, University Hospital, Ludwig-Maximilians-University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Saskia Freytag
- Epigenetics and Genomics Division, Harry Perkins Institute of Medical Research, Nedlands, WA, Australia
| | - Jennifer Lee Spiegel
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Ivelina Stoycheva
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Martin Canis
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Bernhard G Weiss
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Friedrich Ihler
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Frank Haubner
- Department of Otorhinolaryngology, University Hospital, Head and Neck Surgery, Ludwig-Maximilians University of Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
7
|
Tiedt S, Prestel M, Malik R, Schieferdecker N, Duering M, Kautzky V, Stoycheva I, Böck J, Northoff BH, Klein M, Dorn F, Krohn K, Teupser D, Liesz A, Plesnila N, Holdt LM, Dichgans M. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke. Circ Res 2017; 121:970-980. [PMID: 28724745 DOI: 10.1161/circresaha.117.311572] [Citation(s) in RCA: 178] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 07/14/2017] [Accepted: 07/18/2017] [Indexed: 01/22/2023]
Abstract
RATIONALE Currently, there are no blood-based biomarkers with clinical utility for acute ischemic stroke (IS). MicroRNAs show promise as disease markers because of their cell type-specific expression patterns and stability in peripheral blood. OBJECTIVE To identify circulating microRNAs associated with acute IS, determine their temporal course up to 90 days post-stroke, and explore their utility as an early diagnostic marker. METHODS AND RESULTS We used RNA sequencing to study expression changes of circulating microRNAs in a discovery sample of 20 patients with IS and 20 matched healthy control subjects. We further applied quantitative real-time polymerase chain reaction in independent samples for validation (40 patients with IS and 40 matched controls), replication (200 patients with IS, 100 healthy control subjects), and in 72 patients with transient ischemic attacks. Sampling of patient plasma was done immediately upon hospital arrival. We identified, validated, and replicated 3 differentially expressed microRNAs, which were upregulated in patients with IS compared with both healthy control subjects (miR-125a-5p [1.8-fold; P=1.5×10-6], miR-125b-5p [2.5-fold; P=5.6×10-6], and miR-143-3p [4.8-fold; P=7.8×10-9]) and patients with transient ischemic attack (miR-125a-5p: P=0.003; miR-125b-5p: P=0.003; miR-143-3p: P=0.005). Longitudinal analysis of expression levels up to 90 days after stroke revealed a normalization to control levels for miR-125b-5p and miR-143-3p starting at day 2 while miR-125a-5p remained elevated. Levels of all 3 microRNAs depended on platelet numbers in a platelet spike-in experiment but were unaffected by chemical hypoxia in Neuro2a cells and in experimental stroke models. In a random forest classification, miR-125a-5p, miR-125b-5p, and miR-143-3p differentiated between healthy control subjects and patients with IS with an area under the curve of 0.90 (sensitivity: 85.6%; specificity: 76.3%), which was superior to multimodal cranial computed tomography obtained for routine diagnostics (sensitivity: 72.5%) and previously reported biomarkers of acute IS (neuron-specific enolase: area under the curve=0.69; interleukin 6: area under the curve=0.82). CONCLUSIONS A set of circulating microRNAs (miR-125a-5p, miR-125b-5p, and miR-143-3p) associates with acute IS and might have clinical utility as an early diagnostic marker.
Collapse
Affiliation(s)
- Steffen Tiedt
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Matthias Prestel
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Rainer Malik
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Nicola Schieferdecker
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Marco Duering
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Veronika Kautzky
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Ivelina Stoycheva
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Julia Böck
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Bernd H Northoff
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Matthias Klein
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Franziska Dorn
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Knut Krohn
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Daniel Teupser
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Arthur Liesz
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Nikolaus Plesnila
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Lesca Miriam Holdt
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.)
| | - Martin Dichgans
- From the Institute for Stroke and Dementia Research, Klinikum der Universität München (S.T., M.P., R.M., N.S., M.D., V.K., I.S., J.B., A.L., N.P., M.D.), Graduate School of Systemic Neurosciences (S.T.), Institute of Laboratory Medicine, Klinikum der Universität München (B.H.N., D.T., L.M.H.), Department of Neurology, Klinikum der Universität München (M.K.), and Department of Neuroradiology, Klinikum der Universität München (F.D.), Ludwig-Maximilians-Universität LMU, Germany; Munich Cluster for Systems Neurology (SyNergy), Germany (S.T., A.L., N.P., M.D.); and Interdisciplinary Center for Clinical Research (IZKF), University of Leipzig, Germany (K.K.).
| |
Collapse
|